Medicament coating stent capable of preventing blood vessel restenosis and preparation method thereof

Abstract

The invention provides a medicament coating stent capable of preventing blood vessel restenosis and a preparation method thereof. The stent is coated with a PLGA (polylactic acid-glycollic acid) nano particle coating which comprises a medicament carrier and a medicament material; the medicament carrier is PLGA; and the medicament material is one or two of rapamycin or paclitaxel. The preparation method comprises the following steps of: dissolving PLGA with dichloromethane, adding the medicament material, dissolving fully, and performing ultrasonic emulsification by use of an ultrasonic cell disruptor under an ice bath condition so as to prepare a suspension; slowly adding a 2% PVA (Polyvinyl Alcohol) water solution into the suspension while performing magnetic stirring, and emulsifying the suspension again so as to prepare an emulsion; performing rotary evaporation on the emulsion under reduced pressure so as to enable dichloromethane to volatilize completely, so that a nano particular colloidal dispersion system is obtained; adding a 1% coupling agent into the system, and then soaking the stent into the system for 5 minutes, so as to prepare the coating stent; and freeze-drying the coating stent for 10 hours, and preserving the freeze-dried stent at the temperature of 4 DEG C.

Description

technical field [0001] The invention relates to a drug-coated stent in the field of medical materials, in particular to a drug-coated stent for preventing blood vessel restenosis and a preparation method thereof. Background technique [0002] Atherosclerosis is the main cause of ischemic heart disease caused by stenosis or obstruction of the lumen. Percutaneous transluminal angioplasty uses balloon inflation to dilate occluded or stenotic blood vessels to restore normal blood supply, which has been widely accepted and used in the treatment of coronary heart disease. Although the clinical effect of transluminal angioplasty has been satisfactory, its development is limited to a certain extent by its acute vascular occlusion and postoperative stenosis. [0003] In order to solve the problem of restenosis after transluminal angioplasty, domestic and foreign medical circles continue to innovate and explore. Researchers select polymers with good biocompatibility as media, mix dru...

AI Technical Summary

Problems solved by technology

[0004] After the traditional drug-eluting stent is implanted in the human body, the drug release coating on the surface slowly and continuously releases the drug at the stenosis. However, the drug is easily metabolized directly by the blood vessel, the drug utilization rate is low, and the blood drug stability is low. Concentration duration is not ideal

In addition, the drug coating is prone to damage during the delivery and expansion of the stent, and once the drug coating is damaged, it is very likely to cause the coating to fall off in large pieces

Although current drug-eluting stents can significantly reduce restenosis after intraluminal artery angioplasty, the incidence of late stent thrombosis is increased, and the associated acute myocardial infarction and death increase